BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 37016930)

  • 1. Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity.
    Gordon MJ; Jones JE; George B; Peterson C; Burger JA; Jain N; Keating M; Wierda WG; Durand JB; Ferrajoli A
    Cancer; 2023 Jul; 129(14):2192-2200. PubMed ID: 37016930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
    Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum K; Sharman JP; Wierda W; Zhao W; Heerema NA; Luan Y; Liu EA; Dean JP; O'Brien S
    Clin Cancer Res; 2020 Aug; 26(15):3918-3927. PubMed ID: 32209572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
    Maddocks KJ; Ruppert AS; Lozanski G; Heerema NA; Zhao W; Abruzzo L; Lozanski A; Davis M; Gordon A; Smith LL; Mantel R; Jones JA; Flynn JM; Jaglowski SM; Andritsos LA; Awan F; Blum KA; Grever MR; Johnson AJ; Byrd JC; Woyach JA
    JAMA Oncol; 2015 Apr; 1(1):80-7. PubMed ID: 26182309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib.
    Jain P; Thompson PA; Keating M; Estrov Z; Ferrajoli A; Jain N; Kantarjian H; Burger JA; O'Brien S; Wierda WG
    Cancer; 2017 Jun; 123(12):2268-2273. PubMed ID: 28171709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Munir T; Brown JR; O'Brien S; Barrientos JC; Barr PM; Reddy NM; Coutre S; Tam CS; Mulligan SP; Jaeger U; Kipps TJ; Moreno C; Montillo M; Burger JA; Byrd JC; Hillmen P; Dai S; Szoke A; Dean JP; Woyach JA
    Am J Hematol; 2019 Dec; 94(12):1353-1363. PubMed ID: 31512258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
    Coutré SE; Furman RR; Flinn IW; Burger JA; Blum K; Sharman J; Jones J; Wierda W; Zhao W; Heerema NA; Johnson AJ; Tran A; Zhou C; Bilotti E; James DF; Byrd JC; O'Brien S
    Clin Cancer Res; 2017 Mar; 23(5):1149-1155. PubMed ID: 28073846
    [No Abstract]   [Full Text] [Related]  

  • 7. Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study.
    Moldovianu AM; Stoia R; Vasilica M; Ursuleac I; Badelita SN; Tomescu AA; Preda OD; Bardas A; Cirstea M; Coriu D
    Medicina (Kaunas); 2023 Feb; 59(2):. PubMed ID: 36837525
    [No Abstract]   [Full Text] [Related]  

  • 8. Results from a Real-World Multicenter Analysis of 482 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Look at Racial Differences.
    Barrientos JC; Ayed AO; Cha A; Du S; Fang B; Hall R; Marks SM; Peng E; Rhodes JM; Ryan K; Winters SB; Yeung PL; Hou JZ
    Target Oncol; 2023 Sep; 18(5):727-734. PubMed ID: 37728835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.
    Mato AR; Nabhan C; Thompson MC; Lamanna N; Brander DM; Hill B; Howlett C; Skarbnik A; Cheson BD; Zent C; Pu J; Kiselev P; Goy A; Claxton D; Isaac K; Kennard KH; Timlin C; Landsburg D; Winter A; Nasta SD; Bachow SH; Schuster SJ; Dorsey C; Svoboda J; Barr P; Ujjani CS
    Haematologica; 2018 May; 103(5):874-879. PubMed ID: 29419429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
    Byrd JC; Furman RR; Coutre SE; Burger JA; Blum KA; Coleman M; Wierda WG; Jones JA; Zhao W; Heerema NA; Johnson AJ; Shaw Y; Bilotti E; Zhou C; James DF; O'Brien S
    Blood; 2015 Apr; 125(16):2497-506. PubMed ID: 25700432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
    Brown JR; Eichhorst B; Hillmen P; Jurczak W; Kaźmierczak M; Lamanna N; O'Brien SM; Tam CS; Qiu L; Zhou K; Simkovic M; Mayer J; Gillespie-Twardy A; Ferrajoli A; Ganly PS; Weinkove R; Grosicki S; Mital A; Robak T; Osterborg A; Yimer HA; Salmi T; Wang MD; Fu L; Li J; Wu K; Cohen A; Shadman M
    N Engl J Med; 2023 Jan; 388(4):319-332. PubMed ID: 36511784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
    Jones JA; Mato AR; Wierda WG; Davids MS; Choi M; Cheson BD; Furman RR; Lamanna N; Barr PM; Zhou L; Chyla B; Salem AH; Verdugo M; Humerickhouse RA; Potluri J; Coutre S; Woyach J; Byrd JC
    Lancet Oncol; 2018 Jan; 19(1):65-75. PubMed ID: 29246803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
    Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
    Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre.
    Uminski K; Brown K; Bucher O; Hibbert I; Dhaliwal DH; Johnston JB; Geirnaert M; Dawe DE; Banerji V
    Curr Oncol; 2019 Oct; 26(5):e610-e617. PubMed ID: 31708654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia.
    Hou JZ; Ryan K; Du S; Fang B; Marks S; Page R; Peng E; Szymanski K; Winters S; Le H
    Future Oncol; 2021 Dec; 17(35):4959-4969. PubMed ID: 34783255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
    Sharman JP; Brander DM; Mato AR; Ghosh N; Schuster SJ; Kambhampati S; Burke JM; Lansigan F; Schreeder MT; Lunin SD; Zweibach A; Shtivelband M; Travis PM; Chandler JC; Kolibaba KS; Sportelli P; Miskin HP; Weiss MS; Flinn IW
    Lancet Haematol; 2021 Apr; 8(4):e254-e266. PubMed ID: 33631112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Coutre SE; Byrd JC; Hillmen P; Barrientos JC; Barr PM; Devereux S; Robak T; Kipps TJ; Schuh A; Moreno C; Furman RR; Burger JA; O'Dwyer M; Ghia P; Valentino R; Chang S; Dean JP; James DF; O'Brien SM
    Blood Adv; 2019 Jun; 3(12):1799-1807. PubMed ID: 31196847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.
    O'Brien SM; Jaglowski S; Byrd JC; Bannerji R; Blum KA; Fox CP; Furman RR; Hillmen P; Kipps TJ; Montillo M; Sharman J; Suzuki S; James DF; Chu AD; Coutre SE
    JAMA Oncol; 2018 May; 4(5):712-716. PubMed ID: 29470582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ibrutinib discontinuation in patients with relapsed or refractory chronic lymphocytic leukemia treated in a compassionate use program: A report from the Polish Adult Leukemia Study Group (PALG).
    Iskierka-Jażdżewska E; Puła B; Szeremet A; Hus M; Gołos A; Hołojda J; Piszczek W; Steckiewicz P; Wojciechowska M; Zaucha JM; Warzocha K; Jamroziak K
    Adv Clin Exp Med; 2019 Aug; 28(8):1051-1057. PubMed ID: 31199879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.
    Winqvist M; Asklid A; Andersson PO; Karlsson K; Karlsson C; Lauri B; Lundin J; Mattsson M; Norin S; Sandstedt A; Hansson L; Österborg A
    Haematologica; 2016 Dec; 101(12):1573-1580. PubMed ID: 27198718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.